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Mark E. Anderson, MD, PHDH eart failure (HF) and arrhythmias aremonu-mental public health challenges associatedwith suffering, death, and high resource uti-
lization. Currently available treatments are inade-
quate and costly. Furthermore, we lack highly
reliable and readily measurable indices for predicting
which HF patients are at greatest risk for arrhythmias
and sudden death. In this issue of the Journal, Ottesen
et al. (1) present evidence that secretoneurin, a small
peptide measurable in circulating blood, provides
prognostic information for stratifying mortality risk
in patients with HF and life-threatening arrhythmias.
Their story presents tantalizing but incomplete
information to suggest that secretoneurin exerts pro-
tective actions in pathologically stressed myo-
cardium by inhibiting the calmodulin-dependent
protein kinase II (CaMKII).SEE PAGE 339SECRETONEURIN:
WHAT COULD IT ADD CLINICALLY?
Ideally, a biomarker reﬂects activity of a pathway
centrally important to the disease under investigation,
thereby providing therapeutic insights. The small
sample sizes used here prevent clear conclusions for
judging secretoneurin’s clinical utility as a biomarker
for HF or ventricular arrhythmias. However, the
exciting data in 143 patients hospitalized for acute HF
and 155 patients with sudden cardiac death due to
ventricular arrhythmias suggest that secretoneurin
holds promise for predictingmortality in these groups.
In this study, circulating biomarkers previously
validated in large clinical trials, speciﬁcally troponin*Editorials published in the Journal of the American College of Cardiology
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death than secretoneurin, but this apparent superi-
ority of secretoneurin may not hold up in larger
studies. One intriguing aspect of secretoneurin as a
biomarker for heart disease is that it seems to represent
activity of a cellular pathway that is distinct from
troponin or natriuretic peptides. Here Otteson et al. (1)
extend earlier ﬁndings to demonstrate that secreto-
neurin reduces ryanodine receptor-mediated “leak”
of Ca2þ from intracellular (sarcoplasmic reticulum)
stores, a phenomenon linked to HF and triggered ar-
rhythmias (2–4). Furthermore, at concentrations 1,000
to 10,000 times greater than measured in plasma,
secretoneurin has the capacity to inhibit CaMKII
activity.
CA2D SIGNALING AND CAMKII
PLAY KEY ROLES IN HF AND ARRHYTHMIA
Loss of normal myocardial Ca2þ homeostasis is a well-
established fundamental characteristic of structural
heart disease. Defective intracellular Ca2þ homeosta-
sis contributes to mechanisms that promote myocar-
dial dysfunction and arrhythmias. Because Ca2þ is a
key signal for coupling myocardial cell membrane
excitability with myoﬁlament contraction, it is not
surprising that HF and arrhythmias occur together in
patients and in animal models.
A serine-threonine kinase abundant in the heart,
CaMKII’s best understood physiological roles are
related to phosphorylation of proteins involved in
myocardial excitation-contraction coupling and pace-
making. CaMKII seems to behave as a turbocharging
signal during extreme physiological stress, but one
that is dispensable based on the viability of various
genetic mouse models where CaMKII is inhibited or
deleted (5–7). CaMKII expression increases in failing
myocardium. Under cellular conditions present during
HF (e.g., prolonged intracellular Ca2þ transients and
elevated reactive oxygen species), CaMKII reorders
into a molecular conformation with constitutive ac-
tivity (8,9). The increased expression and activity of
CaMKII in failing myocardium favors the twin
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353scourges of mechanical dysfunction and arrhyth-
mias (10). There is now abundant evidence that
myocardial CaMKII inhibition can improve contraction
and suppress arrhythmias, at least in part, by
quelling excessive sarcoplasmic reticulum Ca2þ leak in
animal models (5-7) and in failing human myocar-
dium (11,12). Thus, identifying and characterizing
biomarkers with molecular connections to CaMKII
are of great interest to the HF and arrhythmia
communities.
IS CAMKII INHIBITION BY SECRETONEURIN
DIRECT OR INDIRECT?
The new ﬁndings by Otteson et al. (1) provide evidence
that secretoneurin interacts with a CaMKII pathway in
healthy and injured cardiomyocytes. First, the authors
interestingly observe that secretoneurin binds CaMKII
and the Ca2þ-sensing, CaMKII-activating protein
calmodulin. However, these direct effects on CaMKII
activity are of low potency and do not provide a strong
case that secretoneurin inhibits CaMKII primarily by
direct binding in vivo. Using in vitro CaMKII activity
assays, Otteson et al. found that secretoneurin
at concentrations w10,000-fold greater than were
measured in plasma could inhibit CaMKII by 20% to
30%. Using an alternative measure of CaMKII activity,
CaMKII autophosphorylation, they also found mea-
surable inhibition at secretoneurin concentrations
w1,000-fold greater than in circulating plasma. How-
ever, recent studies have cast doubt on the ﬁdelity of
the CaMKII autophosphorylation epitope (phosphor-
ylation of Thr 287 in CaMKIId) for reporting CaMKII
activity because, at least some, commercially available
antibodies are sensitive to off-target binding in
myocardium (13). In this study, secretoneurin was
effective when added to the perfusate for isolated
hearts at a concentration of w200 nM, w1,000-fold
greater than circulating secretoneurin measured in
patients (0.1 to 0.2 nM) (1,14). All told, the low potency
of secretoneurin as a direct inhibitor of CaMKII casts
doubt on the concept that secretoneurin impacts
myocardial biology primarily by this mechanism.
In contrast, Otteson et al. (1) provide more
convincing evidence that secretoneurin at concen-
trations closer to those detected in patient plasma
(10- to 100-fold higher) reduced sarcoplasmic reticu-
lum Ca2þ leak and enhanced sarcoplasmic reticulumCa2þ content. Excessive sarcoplasmic reticulum Ca2þ
leak can promote arrhythmias and HF, so this aspect
of secretoneurin signaling could provide insights into
future therapies. Furthermore, sarcoplasmic reticu-
lum Ca2þ leak activates CaMKII by calmodulin calci-
ﬁcation and binding, so secretoneurin may indirectly
inhibit CaMKII at plasma concentrations measured in
patients with myocardial disease. Based on these
ﬁndings, I suspect that secretoneurin is more likely to
inhibit CaMKII-mediated signaling by an indirect, as
yet incompletely deﬁned action that reduces sarco-
plasmic reticulum-mediated leak of Ca2þ into the
cytoplasm. It seems probable that the “direct” target
of secretoneurin in myocardium is upstream to
CaMKII.
OPEN QUESTIONS AND NEXT STEPS
The exciting work by Otteson et al. (1) presents new
and important questions. Will secretoneurin provide
clinically useful information in patients with HF and
arrhythmias, above and beyond current biomarkers?
What is the mechanism by which secretoneurin re-
duces sarcoplasmic reticulum Ca2þ leak? What is the
secretoneurin signaling pathway, and can secreto-
neurin and/or other molecular elements of this
pathway be exploited for future therapies? More
research into the biology of secretoneurin will be
required to answer these questions.
Based on our experiences with other biomarkers
relevant to structural heart disease, we can anticipate
that the road from fundamental discovery to poten-
tial clinical application, as a biomarker or a thera-
peutic signal, may be long and complex. The studies
by this group on secretoneurin make an important
contribution, in part, because they provide new in-
sights into a pathway with the potential to promote
HF and arrhythmias by activating CaMKII.
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